Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 28, 2024
Reporting Period: Specific event date of February 28, 2024.
Context: The filing reports a corporate governance amendment approved by the Board of Directors regarding the quorum requirements for stockholder meetings.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused on a bylaw amendment and does not provide a clear value for any financial metrics.
Material Changes
The material change reported is an amendment to Article II, Section 2.8 of the Company's Amended and Restated Bylaws, effective February 28, 2024:
- Previous Quorum Requirement: Presence of holders of a majority of the voting power of shares issued and outstanding.
- New Quorum Requirement: Presence of holders of one-third (1/3) of the voting power of shares issued and outstanding.
- Purpose: To improve the Company's ability to hold stockholder meetings when called.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the operational rationale for the bylaw amendment. No unusual items were reported.
Key Facts for Investor Verification
- Verify the full text of the Bylaw amendment attached as Exhibit 3.1 to confirm the exact legal language of the quorum change.
- Confirm the impact of the reduced quorum threshold on future stockholder meeting logistics and potential governance outcomes.
- Note that this filing does not update the company's financial status or clinical pipeline progress.